02.07.24 -- Are Two Brands Better Than One?

On the Business of Biotech, we welcome Carsten Rudolph, Ph.D., cofounder and CEO of Ethris, a company developing mRNA-based candidates for the treatment of respiratory viral infections and rare pulmonary diseases, in addition to mucosal, multivalent, and mutation-agnostic prophylactic vaccines. Rudolph explains the concept, the business case, and how he's navigating Ethris toward a better treatment and vaccine paradigm in the wake of the pandemic.

Robust, low-maintenance integrations between ERP and specialty software can ensure a free flow of data to enable all-round visibility of activities and events in a life sciences company.

Ensuring optimal yield for engineered viral vectors early in a process is crucial to ensuring their eventual commercial viability and broader patient accessibility.

Learn how a study’s protocol requirements, drug characteristics, packaging specifications, and patient compliance concerns must be identified and addressed to help achieve successful outcomes.

No-code solutions enable faster, less costly system implementation and validation, helping to reduce costs and timelines during the drug and medical device development and approval process.

See how biopharmaceutical companies can apply proven strategies to overcome hidden complexities in mRNA production and discover solutions that can help you rapidly design and build a SU facility.